Valuation: Catalyst Pharmaceuticals, Inc.

Market Cap 3.85B 3.38B 3.12B 2.88B 5.47B 369B 5.58B 37.52B 14.58B 181B 14.47B 14.15B 627B P/E 2026 *
16.1x
P/E 2027 * 13.1x
Enterprise Value 3.85B 3.38B 3.12B 2.88B 5.47B 369B 5.58B 37.52B 14.58B 181B 14.47B 14.15B 627B EV / Sales 2026 *
6.06x
EV / Sales 2027 * 5.37x
Free-Float
94.43%
Yield 2026 *
-
Yield 2027 * -
1 day-0.06%
1 week+0.10%
Current month+0.13%
1 month+0.61%
3 months+24.34%
6 months+39.25%
Current year+34.83%
1 week 31.44
Extreme 31.44
31.5
1 month 31.3
Extreme 31.3
31.5
Current year 22.13
Extreme 22.13
32.56
1 year 19.05
Extreme 19.05
32.56
3 years 11.55
Extreme 11.55
32.56
5 years 4.81
Extreme 4.81
32.56
10 years 0.68
Extreme 0.68
32.56
Manager TitleAgeSince
Chief Executive Officer 65 31/12/2023
Director of Finance/CFO 55 31/12/2023
Chief Tech/Sci/R&D Officer 62 31/05/2025
Director TitleAgeSince
Chairman 78 31/12/2001
Director/Board Member 62 30/09/2002
Director/Board Member 65 18/02/2015
Date Insider Type Main position Quantity % Market Cap.
06-02Fiscal year

Chief Technology Officer

3,795 0.0031%
02-16Fiscal year

Head of Human Resources

1,585 0.0013%
01-04Fiscal year

Chief Executive Officer

94,787 0.0771%
Change 5-day change 1-year change 3-year change Capi.($)
-0.06%+0.10%+51.66%+149.96% 3.85B
-2.48%+6.42%+21.38%-5.48% 68.8B
-2.01%-3.57%+46.21%+217.06% 55.21B
-4.15%+36.30%+36.30%+36.30% 43.46B
+0.27%+8.33%-49.87%-53.43% 41.18B
-8.04%+1.58%+126.32%-40.17% 31.65B
-4.86%-4.42%+49.09%-28.81% 30.37B
+2.68%+2.35%+72.14%+88.22% 23.58B
-1.15%+8.29%+4.42%+184.96% 19.33B
-1.33%+1.11%+66.11%+131.83% 17.16B
Average -2.12%+3.39%+42.38%+68.04% 33.46B
Weighted average by Cap. -2.32%+3.50%+36.33%+51.81%

Financials

2026 *2027 *
Net sales 636M 558M 515M 476M 902M 60.92B 920M 6.19B 2.41B 29.81B 2.39B 2.34B 103B 718M 630M 581M 537M 1.02B 68.74B 1.04B 6.99B 2.72B 33.64B 2.7B 2.64B 117B
Net income 231M 203M 187M 173M 328M 22.13B 334M 2.25B 874M 10.83B 868M 849M 37.6B 316M 277M 256M 237M 449M 30.28B 457M 3.08B 1.2B 14.82B 1.19B 1.16B 51.44B
Net Debt - -
Logo Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing medicines for patients living with rare and difficult-to-treat diseases. The Company markets three drug products: FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone). FIRDAPSE is a treatment for people six years of age or older living with Lambert-Eaton myasthenic syndrome (LEMS). The Company, through its sub-licensee, also offers FIRDAPSE in Canada and Japan. FYCOMPA is a prescription medicine used alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. AGAMREE is a corticosteroid with a structure that retains the potent anti-inflammatory effects of traditional corticosteroids used in Duchenne muscular dystrophy.
Employees
182
Date Price Change Volume
08/07/26 US$31.47 -0.06% 541,786
07/07/26 US$31.49 -0.03% 780,070
06/07/26 US$31.50 +0.16% 923,751
02/07/26 US$31.45 +0.03% 1,616,291
01/07/26 US$31.44 +0.03% 816,919
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
4
Last Close Price
31.49USD
Average target price
31.67USD
Spread / Average Target
+0.56%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CPRX Stock